India Ozempic Market Size Likely to Grow at a CAGR of 17.8% By 2035

Market Size and Growth

The market size of Ozempic in India is estimated at USD 62.3 million in 2025 and it is estimated to grow at a CAGR of 17.8% between 2026 and 2035 with a market size of USD 73.5 million in 2026 and USD 347.5 million in 2035.

India Ozempic Market Revenue and Trends

The Indian market of Ozempic (semaglutide injection) and semaglutide-based GLP-1 receptor agonists concentrates on branded and emerging biosimilar/generic versions, which are applied mainly in glycemic control in adults with type 2 diabetes mellitus who are unable to manage their weight with metformin and/or other oral antidiabetic medications and off-label and steadily-approved applications in chronic weight management in patients with obesity or overweight with weight-related comorbidities. The Indian OZempic market is experiencing phenomenal growth with the rates of type 2 diabetes and obesity increasing drastically, physicians' and patients' awareness of the benefits of GLP-1 RA (glycemic control + significant weight loss + cardiovascular risk reduction) rising at a rapid pace, urbanization and lifestyle change increasing at a rapid pace, growth in the number of private endocrinology and obesity treatment centers, and biosimilar competition and partial insurance coverage in metro cities gradually driving growth in affordability.

What are the Factors That Have a Significant Contribution to the Growth of the India Ozempic market?

High carbohydrate diets, sedentary behavior, genetic disposition, and earlier development of metabolic disease in Indian populations have increased the number of diagnosed and undiagnosed type 2 diabetes (estimated >100 million adults) and Class II/III obesity cases, which has fuelled the demand for GLP-1 receptor agonists such as semaglutide. With more and more endocrinologists and diabetologists prescribing Ozempic/semaglutide as dual glucose and weight-controlling medications, and with growing socialisation of weight-loss pharmacotherapy by social media and celebrities, more patients are seeking access at high out-of-pocket prices.

Innovations have come up through technological and commercial developments such as pre-filled pen devices with dose memory, longer acting formulations in development, patient support programs (reminder apps and diet coaching), and the introduction of biosimilar semaglutide, which are likely to make a big improvement in affordability following the end of patents. Other reasons include a rising count of obesity and metabolic clinics in Tier-1 and Tier-2 cities, increasing private insurance coverage of the select high-cost diabetes drugs, the increase in medical tourism to treat obesity, good marketing by Novo Nordisk and emergent local suppliers, and the government emphasis on non-communicable disease control activities that indirectly propel the promotion of advanced therapy.

Segment Insight

By Product Type

By products, branded Ozempic (semaglutide 0.25/0.5/1 mg pre-filled pens) had so far commanded by far the largest proportion of the Indian Ozempic market as of 2025, due to high physician preference in private specialty care, demonstrated HbA1c reduction, high weight loss, and pre-established cardiovascular outcome results, with further innovation in patient-friendly pen design, digital aids, and dose-escalation guidelines being cited by large proportions of diabetologists and endocrinologists as the best tools for improving adherence and achieving dual metabolic targets in Indian patients.

By Distribution Channel

Among the specialty pharmacies, hospital pharmacies, and high-end retail chains in the metro cities (Apollo Pharmacy, MedPlus, Netmeds, and 1mg), which are used as the main channel of providing cold-chain storage, patient counseling, injection techniques training, and access to manufacturer patient assistance programs, the largest market share is located. Because these means offer professional services to handle temperature-controlled dispensing, insurance pre-authorization assistance (where needed), and subsequent compliance calls, these means have been the preferred channels of dispensing expensive GLP-1 RA medications such as Ozempic.

Report Scope

Recent Developments

• In November 2025: Novo Nordisk India expanded its patient support program for Ozempic with a new digital adherence platform and partial co-pay assistance in select cities, while multiple domestic manufacturers announced Phase III-equivalent biosimilar semaglutide trials targeting commercial launch post-2028, aiming to reduce current out-of-pocket costs by 60–70% and accelerate category penetration in Tier-2 and Tier-3 markets.

List of the prominent players in the India Ozempic Market:

• Novo Nordisk India Pvt Ltd

• Eli Lilly and Company (India) Pvt. Ltd.

• Dr. Reddy's Laboratories Ltd

• Cipla Ltd

• Biocon Ltd

• Sun Pharmaceutical Industries Ltd

• Lupin Ltd

• Torrent Pharmaceuticals Ltd

• Glenmark Pharmaceuticals Ltd

• OneSource Specialty Pharma

• Natco Pharma Ltd

• Emcure Pharmaceuticals Ltd

• Zydus Lifesciences Ltd

• Mankind Pharma Ltd

• Alkem Laboratories Ltd

• Others

The India Ozempic Market is segmented as follows:

By Product Type

• Injectable Semaglutide (Ozempic - branded)

  • 0.5 mg/dose formulation

  • 1.0 mg/dose formulation

  • 2.0 mg/dose formulation

• Oral Semaglutide (Rybelsus - branded)

  • 3 mg tablets

  • 7 mg tablets

  • 14 mg tablets

• Generic Semaglutide (post-March 2026)

  • Injectable generics

  • Oral generics

By Application

• Type 2 Diabetes Mellitus

• Obesity Management

• Cardiovascular Risk Reduction

• Chronic Kidney Disease

• Off-Label Applications

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Institutional Sales (Corporate wellness, Government programs)

By End User

• Adults with Type 2 Diabetes

• Obese/Overweight Individuals

• Cardiovascular Disease Patients

• Chronic Kidney Disease Patients

• Prediabetic Populations